Latest Olanzapine Stories
INDIANAPOLIS, Jan. 7 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) announced today that it received a complete response letter from the U.S.
NEW YORK, Dec.
Corcept Therapeutics Incorporated (NASDAQ: CORT) today reported financial results for the third quarter ended September 30, 2008.
INDIANAPOLIS, Oct. 23 /PRNewswire-FirstCall/ -- Eli Lilly and Company today announced financial results for the third quarter of 2008. Due to significant strategic actions taken by the company in 2008, financial results are presented on both a reported basis and a pro forma non-GAAP basis.
INDIANAPOLIS, Oct. 21 /PRNewswire-FirstCall/ -- Eli Lilly and Company today announced that it is in advanced discussions to resolve the ongoing investigations led by the U.S. Attorney's Office for the Eastern District of Pennsylvania (EDPA) related to past U.S.
By Wall, J K Lilly Endowment Inc. is still on its journey to sell off $2 billion of its Eli Lilly and Co. shares. But after a slow start and a few stops for rest, it may take a little longer to get there than originally thought.
Drugmaker Eli Lilly & Co. cleared a legal cloud hanging over its top-selling drug Zyprexa, an antipsychotic medication, when it announced a $62 million settlement Tuesday. Lilly agreed to pay 32 states and Washington to resolve an investigation into the company's marketing practices.
Eli Lilly and Company has resolved a multi-state investigation involving 32 states and the District of Columbia related to the sales, marketing and promotion of its antipsychotic medication Zyprexa.
INDIANAPOLIS, Ind., Oct. 7 /PRNewswire-FirstCall/ -- Eli Lilly and Company today announced that it has resolved a multi-state investigation involving 32 states and the District of Columbia (DC) related to the sales, marketing and promotion of its antipsychotic medication Zyprexa(R) (olanzapine).
By Julie Schmit Drugmaker Eli Lilly agreed Monday to pay $6.5 billion for biotech-drug maker ImClone Systems, beating an offer by Bristol-Myers Squibb and boosting its stable of cancer drugs. The all-cash deal, which has been approved by both companies' boards, values ImClone at $70 a share.
- a meat pie that is usually eaten at Christmas in Quebec